Oncolix, Inc. to Present at the 10th Annual LD Micro Main Event

November 27, 2017 12:45 PM

LOS ANGELES, CA / ACCESSWIRE / November 27, 2017 / Oncolix Inc. (OTC PINK: AEPP), a clinical-stage biotechnology company focused on women's cancers, announced today that it will be presenting at the 10th annual LD Micro Main Event on Wednesday, December 6, at 3:30PM PST / 6:30PM EST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Michael T. Redman, CEO of Oncolix, will be presenting, as well as meeting with investors. The LD Micro Main...

Read more

Orpheris Receives Orphan Drug Designation from the U.S. FDA for its Lead Drug Candidate, OP-101, for the Treatment of ccALD

November 27, 2017 7:00 AM

REDWOOD CITY, CA / ACCESSWIRE / November 27, 2017 / Orpheris Inc., a biopharmaceutical company dedicated to developing dendrimer technology to treat neuroinflammatory orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to OP-101, the Company's lead drug candidate, for the treatment of patients with childhood cerebral andrenoleukodystrophy (ccALD), not eligible for bone marrow...

Read more

MorphoSys Announces That Its Licensee Janssen Has Received Approval for Tremfya(R) (Guselkumab) in Europe for the Treatment of Moderate-to-Severe Plaque Psoriasis

November 23, 2017 9:55 AM

MorphoSys Entitled to Royalties on Net Sales of Janssen's Tremfya(R) PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 23, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY) announced today that its licensee Janssen-Cilag International NV (Janssen), has reported that the European Commission has granted approval of Tremfya(R) (guselkumab) in the European Union for the treatment of adults with moderate-to-severe plaque...

Read more

Vitro Biopharma Files Patent for Its Novel Stem Cell Line with Broad Application to Stem Cell Therapies

November 21, 2017 9:30 AM

GOLDEN, CO / ACCESSWIRE / November 21, 2017 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro Biopharma, announced the filing of a USPTO patent application regarding a novel stem cell line and its application to treatment of a variety of conditions including skeletal muscular, neurological, immune system dysfunction and other diseases or injuries as well. The new stem cell line is derived from adult stem cells that are naturally present in...

Read more

Molecular Partners Expands and Advances Robust Pipeline of DARPin(R) Therapies in Oncology and Ophthalmology

November 9, 2017 1:00 AM

- Company Begins Development of MP0310, First DARPin® Therapy in Early-stage Immuno-oncology Portfolio - R&D Update and Webcast Today Highlights Continued Progress in Pipeline in Oncology and Ophthalmology ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / November 9, 2017 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announces...

Read more

MorphoSys Announces Presentation of Clinical Data on Proprietary Blood Cancer Compound MOR208 at Upcoming American Society of Hematology Annual Meeting 2017

November 2, 2017 3:15 AM

- Abstract on preliminary data from ongoing phase 2 trial with antibody MOR208 in combination with lenalidomide in relapsed/refractory DLBCL accepted for poster presentation at ASH 2017 - Poster presentation will take place on December 11, 2017, 6:00-8:00pm EST (December 12, 0:00-2:00am CET) - Conference call by MorphoSys scheduled for December 12, 2017, 11:00am EST (5:00pm CET) PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 2, 2017 /...

Read more

Shareholders of Molecular Partners Approved the Elections of Bill Burns and Patrick Amstutz to the Board of Directors

October 31, 2017 11:45 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 31, 2017 / At today's Extraordinary General Meeting of Molecular Partners (SWX: MOLN), the shareholders of the company approved the election of William (Bill) Burns, former CEO of Roche Pharmaceuticals, and Patrick Amstutz, CEO of Molecular Partners, as new members of the Board of Directors with large majorities. The Board of Directors has appointed Bill Burns as Vice-Chairman and will...

Read more

Dr. Markus Enzelberger Appointed MorphoSys's Chief Scientific Officer

October 30, 2017 7:05 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 30, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY) today announced that Dr. Markus Enzelberger has been appointed as Chief Scientific Officer (CSO), as of November 1, 2017. Dr. Enzelberger has been the Company's Interim CSO since April 15, 2017. He will succeed Dr. Marlies Sproll, who has been on temporary leave from her CSO position for family reasons since April...

Read more

MorphoSys to Host Q3 2017 Conference Call on November 7, 2017

October 26, 2017 8:20 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 26, 2017 / MorphoSys AG (FSE: MOR) ; Prime Standard Segment, TecDAX) will publish its first nine months' 2017 results on November 7, 2017 at 7:00 am CET. At 2:00 pm CET (1:00 pm GMT, 8:00 am EST), the Management Board of MorphoSys AG will host a public conference call and webcast to present MorphoSys's financial results for the first nine month of 2017 and provide further details on the Company's...

Read more

INTERIM MANAGEMENT STATEMENT Q3 2017: Significant Progress Across All Clinical Programs - New Pre-clinical Immuno-oncology Data to be Presented During R&D Day in New York

October 26, 2017 1:00 AM

Research & Development Highlights:- MP0250: Phase 2 Study in Multiple Myeloma Progressing Well and According to Plan- MP0250: FDA Accepted the Company's IND (Submitted in August 2017) for Phase 2 Study Evaluating MP0250 in EGFR-Mutated Non-Small Cell Lung Cancer (EGFR mut NSCLC);- On Track to Dose First Patient in Q1 2018- MP0274: First Patient Dosed in Phase 1 Trial of This Multi-DARPin® Candidate for the Treatment of HER2-Positive...

Read more

MorphoSys Receives FDA Breakthrough Therapy Designation for Its Antibody MOR208 in Relapsed/Refractory DLBCL

October 23, 2017 5:06 PM

Designation is Intended to Expedite Development of MorphoSys' Most Advanced Blood Cancer Drug Candidate MOR208 in Combination with Cancer Drug Lenalidomide PLANEGG, MUNICH, GERMANY / ACCESSWIRE / October 23, 2017 / MorphoSys AG (FRA: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to MOR208, in combination with lenalidomide, for...

Read more

Qrons Announces Signing of Option Agreement with Dartmouth College

October 20, 2017 7:00 AM

Agreement Will Allow for Further Research Developing Innovative 3D Printable, Biocompatible Materials and Stem Cell Delivery Techniques for Qrons' Traumatic Brain Injury Treatment. Qrons to also Finance Patent Prosecution by Dartmouth MIAMI, FL / ACCESSWIRE / October 20, 2017 / Qrons Inc. (OTC PINK: QRON) ("Qrons " or the "Company"), a preclinical biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a...

Read more

First Patient Dosed in Phase 1 Clinical Study of Molecular Partners’ Second Proprietary Oncology Asset MP0274

October 12, 2017 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 12, 2017 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, announced today that the first patient was dosed in the phase 1 clinical study of its oncology asset, MP0274. MP0274 is a proprietary DARPin® drug candidate for the treatment of HER2-positive cancer with a new mode of action compared to...

Read more

Pressure BioSciences' Penetration in European Biopharma and High Pressure Markets Continuing to Expand via Multiple Scientific Presentations in Germany, Poland, and Ireland

October 10, 2017 10:52 AM

SOUTH EASTON, MA / ACCESSWIRE / October 10, 2017 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced that multiple presentations have highlighted features and benefits of the Company's recently-released, next-generation Barocycler 2320EXTREME...

Read more

Molecular Partners Publishes Invitation to Extraordinary General Meeting to be held on October 31, 2017

October 9, 2017 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 9, 2017 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs, known as DARPin® therapies, today published the Invitation to the Extraordinary General Meeting which will be held on Tuesday, October 31, 2017, 2.00 pm CET (doors open at 1.00 pm), at the registered office of the company, 5th floor, Wagistrasse 14, 8952...

Read more

Bill Burns Nominated for Election to Molecular Partners' Board of Directors as Vice-Chairman with Nomination to Chairman in 2018

October 3, 2017 1:00 AM

CEO and Co-founder Patrick Amstutz Also to Stand for Election to Board at Extraordinary General Meeting on October 31, 2017 ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 3, 2017 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today announced that its Board of Directors has nominated William (Bill) Burns, former CEO of Roche...

Read more

Pressure BioSciences, Inc. Issued First Two Patents on Widely-Applicable, High Pressure-Based Ultra Shear Technology ("UST")

October 2, 2017 8:20 AM

Company Believes UST Can Be Used to Create or Improve a Broad Range of Medical, Consumer, and Industrial Products through the Preparation of High-Quality Nanoemulsions and Safe "Clean Label" Food SOUTH EASTON, MA / ACCESSWIRE / October 2, 2017 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to...

Read more

Mount Tam Biotechnologies to Present at The MicroCap Conference on October 5th in New York City at the Essex House

September 28, 2017 11:33 AM

NEW YORK, NY / ACCESSWIRE / September 28, 2017 / Mount Tam Biotechnologies (OTC PINK: MNTM) will be presenting at this year's MicroCap Conference on October 5th in New York City. CONFERENCE OVERVIEW AND STRUCTURE The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from...

Read more

MorphoSys and Galapagos Report First Promising Signs of Clinical Activity in a Phase 1 Study With IL-17C-Antibody MOR106 in Atopic Dermatitis Patients

September 27, 2017 7:35 AM

- Generally well-tolerated with no clinically relevant safety signals in Phase 1 study - At the highest dose level, 5 out of 6 patients (83%) reached an improvement of at least 50% in atopic dermatitis symptoms (EASI-50) by week 4 - Results support progression to Phase 2 study - Novel mechanism of action evaluated in patients: MOR106 is the first human monoclonal antibody against IL-17C in clinical development worldwide PLANEGG/MUNICH,...

Read more

ITUS Corporation to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK Capital

September 25, 2017 9:00 AM

NEW YORK, NY / ACCESSWIRE / September 25, 2017 / ITUS Corporation (NASDAQ: ITUS) announced today that it will be presenting at the 2017 Disruptive Growth Company Showcase NYC at 2:30 PM EDT/ 11:30 AM PDT on September 27, 2017 at the Grand Hyatt 109 E 42nd St. Dr. Amit Kumar, CEO of ITUS, will be presenting, as well as meeting with investors. Each company will be provided with a 30-minute time slot to present to an audience of investors and...

Read more